Inari Medical, Inc. (NASDAQ:NARI) Shares Sold by Amundi

Amundi lessened its stake in Inari Medical, Inc. (NASDAQ:NARI) by 10.3% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 201,366 shares of the company’s stock after selling 23,076 shares during the quarter. Amundi’s holdings in Inari Medical were worth $10,280,000 as of its most recent filing with the SEC.

A number of other institutional investors have also modified their holdings of the stock. PNC Financial Services Group Inc. raised its stake in shares of Inari Medical by 5.3% in the 4th quarter. PNC Financial Services Group Inc. now owns 2,550 shares of the company’s stock valued at $130,000 after purchasing an additional 128 shares in the last quarter. Lisanti Capital Growth LLC acquired a new stake in shares of Inari Medical in the 4th quarter valued at about $3,969,000. Raymond James Financial Inc. acquired a new stake in shares of Inari Medical in the 4th quarter valued at about $1,001,000. Arizona State Retirement System raised its stake in shares of Inari Medical by 0.9% in the 4th quarter. Arizona State Retirement System now owns 15,196 shares of the company’s stock valued at $776,000 after purchasing an additional 129 shares in the last quarter. Finally, Assetmark Inc. raised its stake in shares of Inari Medical by 5.6% in the 4th quarter. Assetmark Inc. now owns 20,473 shares of the company’s stock valued at $1,045,000 after purchasing an additional 1,091 shares in the last quarter. Institutional investors and hedge funds own 90.98% of the company’s stock.

Inari Medical Stock Performance

Shares of NASDAQ:NARI opened at $79.97 on Friday. The firm’s 50 day moving average is $78.86 and its two-hundred day moving average is $58.54. Inari Medical, Inc. has a 52 week low of $36.73 and a 52 week high of $79.99. The firm has a market capitalization of $4.68 billion, a P/E ratio of -59.24 and a beta of 1.02.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on NARI shares. BTIG Research reiterated a “neutral” rating on shares of Inari Medical in a research note on Wednesday, January 8th. Wells Fargo & Company reiterated an “equal weight” rating and set a $80.00 price objective (up previously from $65.00) on shares of Inari Medical in a research note on Tuesday, January 7th. Truist Financial increased their price objective on shares of Inari Medical from $50.00 to $63.00 and gave the stock a “hold” rating in a research note on Wednesday, December 18th. Oppenheimer started coverage on shares of Inari Medical in a research note on Tuesday, December 17th. They set an “outperform” rating and a $75.00 price objective on the stock. Finally, Piper Sandler increased their price objective on shares of Inari Medical from $52.00 to $80.00 and gave the stock a “neutral” rating in a research note on Tuesday, January 7th. Twelve research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $68.00.

Insider Buying and Selling at Inari Medical

In other news, Director William Hoffman sold 60,000 shares of the stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $55.66, for a total value of $3,339,600.00. Following the completion of the transaction, the director now directly owns 441,233 shares in the company, valued at $24,559,028.78. This trade represents a 11.97 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Andrew Hykes sold 3,000 shares of the stock in a transaction that occurred on Friday, December 20th. The shares were sold at an average price of $55.29, for a total transaction of $165,870.00. Following the completion of the transaction, the chief executive officer now owns 439,310 shares of the company’s stock, valued at $24,289,449.90. This trade represents a 0.68 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 263,000 shares of company stock worth $15,599,470. 10.60% of the stock is owned by company insiders.

About Inari Medical

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.